Healthcare / BiotechnologyKOSDAQ
$19400.00
-800.00 (-3.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-4.9B · quality 76.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$248.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-33.2%
↓Gross Margin
4.6%
↓Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.3%
FCF CAGR
—
FCF margin
-371.4%
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.95B · net income $-7.57B · FCF $-7.22B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.95B | $1.95B | $2.29B | $1.47B | $1.76B |
| Net Income | $-7.57B | $-7.57B | $-7.27B | $-3.63B | $-6.38B |
| EBITDA | $-6.66B | $-6.66B | $-6.51B | $-2.87B | $-5.26B |
| EPS | -591.00 | -591.00 | -716.00 | -366.00 | -658.00 |
| Gross Margin | 4.6% | 4.6% | 42.2% | 21.3% | 11.8% |
| Operating Margin | -423.9% | -423.9% | -311.7% | -342.8% | -300.8% |
| Net Margin | -389.4% | -389.4% | -317.3% | -246.9% | -362.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.37 | 0.37 | 0.07 | 0.20 | 1.01 |
| Current Ratio | 11.95 | 11.95 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.22B | $-7.22B | $-4.94B | $-4.37B | $-5.17B |
| Returns | |||||
| ROE | -33.2% | -33.2% | -24.6% | -48.5% | -233.1% |
| Valuation | |||||
| P/B | 10.91 | 10.91 | 4.42 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -15.1% | -15.1% | 55.6% | -16.5% | — |
| EPS Growth | 17.5% | 17.5% | -95.6% | 44.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+5.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-716.00 → -591.00
Residual
+5.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.